Viridian Therapeutics (VRDN) Competitors $13.64 +0.10 (+0.70%) As of 10:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN vs. RDNT, SHC, PRVA, BTSG, SGRY, WGS, CON, VCYT, LFST, and PGNYShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), Sotera Health (SHC), Privia Health Group (PRVA), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), GeneDx (WGS), Concentra Group Holdings Parent (CON), Veracyte (VCYT), LifeStance Health Group (LFST), and Progyny (PGNY). These companies are all part of the "healthcare" industry. Viridian Therapeutics vs. RadNet Sotera Health Privia Health Group BrightSpring Health Services Surgery Partners GeneDx Concentra Group Holdings Parent Veracyte LifeStance Health Group Progyny RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Do analysts prefer RDNT or VRDN? RadNet presently has a consensus target price of $69.75, indicating a potential upside of 33.16%. Viridian Therapeutics has a consensus target price of $35.70, indicating a potential upside of 163.47%. Given Viridian Therapeutics' higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than RadNet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RadNet 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Viridian Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is RDNT or VRDN more profitable? RadNet has a net margin of -0.25% compared to Viridian Therapeutics' net margin of -85,127.16%. RadNet's return on equity of 4.29% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RadNet-0.25% 4.29% 1.45% Viridian Therapeutics -85,127.16%-70.12%-41.49% Does the MarketBeat Community favor RDNT or VRDN? RadNet received 281 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Viridian Therapeutics an outperform vote while only 66.29% of users gave RadNet an outperform vote. CompanyUnderperformOutperformRadNetOutperform Votes35666.29% Underperform Votes18133.71% Viridian TherapeuticsOutperform Votes7578.95% Underperform Votes2021.05% Do institutionals & insiders have more ownership in RDNT or VRDN? 77.9% of RadNet shares are held by institutional investors. 5.1% of RadNet shares are held by company insiders. Comparatively, 0.7% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings & valuation, RDNT or VRDN? RadNet has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadNet$1.83B2.12$3.04M$0.031,746.00Viridian Therapeutics$302K3,660.74-$237.73M-$3.77-3.59 Does the media favor RDNT or VRDN? In the previous week, RadNet had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 15 mentions for RadNet and 13 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.42 beat RadNet's score of 1.37 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RDNT or VRDN? RadNet has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. SummaryRadNet beats Viridian Therapeutics on 13 of the 19 factors compared between the two stocks. Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$2.88B$5.56B$7.83BDividend YieldN/A31.29%5.11%4.22%P/E Ratio-3.1413.2822.4418.48Price / Sales3,660.74188.21393.95103.59Price / CashN/A57.5638.1834.62Price / Book3.024.676.774.25Net Income-$237.73M-$22.21M$3.22B$248.23M7 Day Performance-0.07%-1.91%1.45%0.89%1 Month Performance7.88%3.24%3.96%3.53%1 Year Performance-1.88%11.50%16.07%5.08% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics1.2599 of 5 stars$13.65+0.7%$35.70+161.6%+2.2%$1.11B$302,000.00-3.1550Upcoming EarningsNews CoveragePositive NewsRDNTRadNet4.0251 of 5 stars$47.36-4.9%$69.75+47.3%+8.0%$3.51B$1.83B-676.478,970Positive NewsGap DownSHCSotera Health2.3998 of 5 stars$10.32-1.5%$15.20+47.3%+2.7%$2.93B$1.10B41.283,000PRVAPrivia Health Group4.1117 of 5 stars$22.71-4.1%$27.00+18.9%+27.6%$2.76B$1.74B227.12810Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive NewsBTSGBrightSpring Health Services2.5439 of 5 stars$15.62-5.9%$21.67+38.7%+64.0%$2.73B$11.27B-60.0835,000Upcoming EarningsNews CoveragePositive NewsSGRYSurgery Partners3.2333 of 5 stars$20.20-4.8%$34.75+72.0%-12.0%$2.58B$3.11B-42.0812,200News CoverageWGSGeneDx2.1962 of 5 stars$91.04-4.6%$72.33-20.5%+291.6%$2.56B$305.45M-46.451,200News CoveragePositive NewsGap DownCONConcentra Group Holdings ParentN/A$19.88-2.5%$28.50+43.4%N/A$2.53B$1.90B13.1711,000Upcoming EarningsPositive NewsVCYTVeracyte3.9687 of 5 stars$30.60-1.7%$42.60+39.2%+55.9%$2.39B$445.76M-204.00790Upcoming EarningsShort Interest ↑Gap DownLFSTLifeStance Health Group2.2202 of 5 stars$6.16-8.1%$8.58+39.3%+6.3%$2.37B$1.25B-23.696,640Upcoming EarningsPositive NewsPGNYProgyny1.1831 of 5 stars$21.37-0.3%$23.64+10.6%-28.8%$1.83B$1.17B36.85310Upcoming EarningsPositive News Related Companies and Tools Related Companies RDNT Competitors SHC Competitors PRVA Competitors BTSG Competitors SGRY Competitors WGS Competitors CON Competitors VCYT Competitors LFST Competitors PGNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRDN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRDN Stock Free VRDN Stock Alerts